Amicus Therapeutics is a biopharmaceutical company out of Cranbury, New Jersey. They specialize in helping those with specific diseases. These diseases are known as rare and orphan diseases due to fact that they affect such a small portion of the population. They particularly focus on lysosomal storage disorders, which are a group of rare metabolic disorders. They had no marketed products as of February of 2014, however were taking an in-depth look at Migalastat, a product that could help treat Fabry disease. View the market summary of Amicus Therapeutics at marketwatch.com.
The company extended its site locations in 2008, locating another building in San Diego. They received a $500,000-dollar grant from The Michael J. Fox Foundation in 2010, which was intended to support their studies in medicine. In the same year, they were given yet another grant from the Alzheimer’s Drug Discovery Foundation of $210,300. The grant was made out to help Amicus Therapeutics with their pre-clinical work. This company is very dedicated to the work that they do. They aim to help those people suffering from rare diseases of which have not been cured at this point in time.
Amicus Therapeutics has done something that many other companies have not, in that they have taken on the challenge of solving rare diseases. While battling to find advancements, they have kept relationships with patients are their families at the top priority. Numerous patients had amazing things to say about the company, and how it helped them change their lives. The team members are very persistent in the work they do, and they work hard to find ways to make change. Amicus Therapeutics has a belief statement in which they live by, sort of like their motto. They have listed a number of sayings that they have pledged to stay true to. A few of the sayings include, “We encourage and embrace constant innovation” and “We encourage and embrace constant innovation”. All in all, Amicus Therapeutics has a vision to make an impact in this world, and they work hard to achieve that. Visit Google Finance to know more about Amicus Therapeutics.